The Data Maven: A $40 HIV Prevention Shot for the World. But What About America?

The U.S. has facilitated global access to an affordable HIV prevention drug, yet domestic administrative and insurance barriers continue to hinder access for many Americans. The article argues that the U.S. must address these internal healthcare inequities while promoting global health initiatives.
Why it matters
It highlights the disparity between U.S. foreign health policy and domestic healthcare accessibility, particularly for vulnerable populations.
Earlier this month, the United States helped deliver a major accomplishment in the global fight against HIV. The U.S. Food and Drug Administration approved a generic version of lenacapavir, allowing one of the world’s most effective injectable HIV prevention medications to reach approximately 120 low- and middle-income countries for about $40 per person annually . Such a low price gives more people access to the important drug, which can help better control the spread of HIV.
But there is an uncomfortable irony behind this achievement that can’t be ignored: While access to HIV prevention is expanding globally, funding cuts and policy changes in the U.S. threaten to make prevention harder to access for many Americans who need it most.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in